Real-World Evaluation of Glycemic Outcomes and Extra-Glycemic Parameters in Diabetic Patients Treated with the Combined Formulation Degludec –Liraglutide (Ideglira)
ConclusionThe findings from this study show that in a real-world setting, the switch to IDegLira treatment is a valid option for patients who are failing to achieve glycemic control targets and/or struggling with the side effects, such as weight gain and hypoglycemia, of other insulin therapies.
Source: Diabetes Therapy - Category: Endocrinology Source Type: research
More News: Clinical Trials | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Insulin | Italy Health | Study | Victoza